Registry for managing liver failure in Chinese patients

Registry Study for Optimal Management of Liver Failure in the Chinese Population (RESOLVE-C)

This study is trying to create a database to better understand liver failure in Chinese patients, looking at their health details and how infections and muscle loss affect their recovery.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Sex: All
• Sponsor: First Affiliated Hospital Xi'an Jiaotong University (other)
• Locations: 14 sites (Xi'an, Shaanxi and 13 other locations)
• Trial ID: NCT05740696 on ClinicalTrials.gov

What this trial studies

This observational study aims to create a real-world case registry database for inpatients suffering from liver failure in China. It will utilize an electronic clinical data collection system across multiple centers to analyze clinical characteristics, the epidemiology of infections, and the effects of sarcopenia on patient outcomes. The findings will help optimize treatment strategies, including antiviral therapies and artificial liver support, and will inform future studies on related clinical issues. The study focuses on understanding the complexities of liver failure and its management in the Chinese population.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with liver failure exhibiting severe symptoms and specific laboratory findings.

Not a fit: Patients with complications that significantly affect clinical assessment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved management strategies and better outcomes for patients with liver failure.

How similar studies have performed: While similar observational studies have been conducted, this specific approach focusing on the Chinese population and the multifaceted aspects of liver failure is relatively novel.

Eligibility criteria

Inclusion Criteria:

Patients with a diagnosis consistent with liver failure and pre-liver failure:

* Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
* Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
* Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.

Exclusion Criteria:

* An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.

Where this trial is running

Xi'an, Shaanxi and 13 other locations

• First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi, China (RECRUITING)
• Ankang Central Hospital — Ankang, China (RECRUITING)
• Xiangya Hospital of Central South University — Changsha, China (NOT_YET_RECRUITING)
• Hanzhong 3201 Hospital — Hanzhong, China (NOT_YET_RECRUITING)
• Qilu Hospital of Shandong University — Jinan, China (NOT_YET_RECRUITING)
• First Hospital of Lanzhou University — Lanzhou, China (NOT_YET_RECRUITING)
• Weinan Central Hospital — Weinan, China (NOT_YET_RECRUITING)
• Air Force Medical University Tangdu Hospital — Xi'an, China (NOT_YET_RECRUITING)
• Shaanxi provincial people's hospital — Xi'an, China (NOT_YET_RECRUITING)
• The Second Affiliated Hospital of Xi'an Jiaotong University — Xi'an, China (RECRUITING)
• Xi 'an International Medical Center Hospital — Xi'an, China (NOT_YET_RECRUITING)
• Xianyang Central Hospital — Xianyang, China (RECRUITING)
• The Affiliated Hospital of Yan'an University — Yanan, China (NOT_YET_RECRUITING)
• General Hospital of Ningxia Medical University — Yinchuan, China (NOT_YET_RECRUITING)

Study contacts

• Study coordinator: Yingli He, Pro.

Conditions: Liver Failure